<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="protocol"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="hwp">bmjopen</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5942461</article-id><article-id pub-id-type="publisher-id">bmjopen-2017-018326</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2017-018326</article-id><article-categories><subj-group subj-group-type="heading"><subject>Dentistry and Oral Medicine</subject><subj-group><subject>Protocol</subject></subj-group></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1686</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Photomodulation in the treatment of chronic pain in patients with temporomandibular disorder: protocol for cost-effectiveness analysis </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib id="author-55977762" contrib-type="author"><name><surname>Sobral</surname><given-names>Ana Paula Taboada</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-55977823" contrib-type="author"><name><surname>de Godoy</surname><given-names>Camila Leal H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib id="author-55977838" contrib-type="author"><name><surname>Fernandes</surname><given-names>Kristianne P Santos</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-46230318" contrib-type="author"><name><surname>Bussadori</surname><given-names>Sandra Kalil</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-46230321" contrib-type="author"><name><surname>Ferrari</surname><given-names>Raquel Agnelli Mesquita</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-46214497" contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3476-9064</contrib-id><name><surname>Horliana</surname><given-names>Anna Carolina Ratto Tempestini</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-55977969" contrib-type="author"><name><surname>Monken</surname><given-names>Sonia F</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib id="author-55972405" contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7774-4345</contrib-id><name><surname>Motta</surname><given-names>Lara J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="department">Postgraduate program in Biophotonics Applied to Health Sciences</institution>, <institution>Universidade Nove de Julho - UNINOVE</institution>, <addr-line content-type="city">São Paulo</addr-line>, <country>Brazil</country>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="department">Dentistry School from Universidade Nove de Julho - UNINOVE</institution>, <institution>Universidade Nove de Julho - UNINOVE</institution>, <addr-line content-type="city">São Paulo</addr-line>, <country>Brazil</country>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="department">Professional Master Health Administration Program</institution>, <institution>Universidade Nove de Julho - UNINOVE</institution>, <addr-line content-type="city">São Paulo</addr-line>, <country>Brazil</country>
</aff><author-notes><corresp><label>Correspondence to</label> Dr Lara J Motta; <email>larajmotta@terra.com.br</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>5</day><month>5</month><year>2018</year></pub-date><volume>8</volume><issue>5</issue><elocation-id>e018326</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>23</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>05</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bmjopen-2017-018326.pdf"/><self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2017-018326.reviewer_comments.pdf"/><self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2017-018326.draft_revisions.pdf"/><abstract><sec><title><text><SENT sid="1" pm="."><plain>Introduction </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Epidemiological data show that the signs and symptoms of temporomandibular disorder (TMD) start becoming apparent from 6 years of age, and during adolescence these signs and symptoms are similar to those of adults. </plain></SENT>
<SENT sid="3" pm="."><plain>The present study aims to estimate the direct costs for treatment of chronic muscle pain with photobiomodulation therapy, occlusal splint and placebo in patients with TMD; to evaluate the effectiveness of photobiomodulation therapy and occlusal splint for treatment of muscle pain in patients with TMD; to analyse the cost-effectiveness of the two proposed treatments for pain; and to describe and compare the results of the analyses of these treatments. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="4" pm="."><plain>Methods and analysis </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>This is a prospective trial of clinical and economic analyses that will include 135 patientswith TMD aged between 15 years and 25 years, randomly assigned to a treatment group: G1 (photobiomodulation), G2 (occlusal splint) and G3 (placebo). </plain></SENT>
<SENT sid="6" pm="."><plain>The analyses will be based on the cost of each treatment during the 12-month period. </plain></SENT>
<SENT sid="7" pm="."><plain>The outcome of the analysis of effectiveness will be pain, measured periodically by means of clinical examination of Research Diagnostic Criteria for Temporomandibular Disorders. </plain></SENT>
<SENT sid="8" pm="."><plain>The cost-effectiveness ratio will be calculated using, as end points, pain and the ratio of the differences in costs between the groups studied. </plain></SENT>
<SENT sid="9" pm="."><plain>The evaluation of the impact of the treatment on quality of life will be determined by applying the adapted EuroQol-5D. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Ethics and dissemination </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>This protocol has been ethically approved by the local medical ethical committee, protocol number 2.014.339. </plain></SENT>
<SENT sid="12" pm="."><plain>Results will be submitted to international peer-reviewed journals and presented at international conferences. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Trial registration number </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain><ext-link ext-link-type="uri" xlink:href="NCT03096301" specific-use="clinicaltrial">NCT03096301</ext-link>. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><kwd>temporomandibular jointdysfunction syndrome</kwd><kwd>cost effectiveness analysis</kwd><kwd>photobiomodulation therapy</kwd><kwd>pain</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s1"><title><text><SENT sid="15" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>Temporomandibular disorder (TMD) is a term used to define a number of clinical signs and symptoms that affect the masticatory muscles, the temporomandibular joint (TMJ) and associated structures.1–6 The most common signs and symptoms are sensitivity of the masticatory muscles, pain in one or both TMJs, limited mandibular movement, articular noises,6–8 headache,6 9 10 associated dizziness, hearing loss and sometimes tinnitus.1 11 Signs and symptoms of TMD are seen at all ages, however, the prevalence of this disorder, considered low in children, increases with age in adolescents and young adults.12 13 The changes caused by TMD, especially pain, can interfere with the quality of life of these patients.14 </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>Various treatment options have been proposed, mainly for pain control, such as occlusal splints, acupuncture, kinesiotherapy, massage therapy, postural training, psychotherapy, joint mobilisations, drug therapy and laser therapy.15 16 Photobiomodulation therapy is a non-invasive, non-pharmacological treatment that, according to various studies, has shown beneficial results in the treatment of pain associated with TMD.4–7 16–24 Photobiomodulation is a radiation located between the visible and infrared portions of the spectrum of electromagnetic waves, with characteristics of monochromaticity, coherence, one-directionality and variable wavelength.6 Inflammation modulation and analgesic effects are cited among the therapeutic results of photobiomodulation treatment on TMD.5 6 22 25 26 </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>Laser therapy has demonstrated the capacity to assist in symptomatic treatment of pain, promoting a considerable degree of comfort for the patient immediately after its application. </plain></SENT>
<SENT sid="19" pm="."><plain>The main advantage of laser applications in the treatment of TMD is that this type of therapy is non-invasive and low-cost, and is currently widely used in dental clinics, reducing the demand for surgery or drugs for the treatment of pain relief and tissue regeneration. </plain></SENT>
<SENT sid="20" pm="."><plain>The application of laser therapy in patients with TMD has demonstrated the ability to relieve pain within minutes of its application, promoting significant well-being. </plain></SENT>
<SENT sid="21" pm="."><plain>Moreover, it is an adjuvant pain-relief treatment in which the analgesic action of the laser enables the patient to return to their duties, providing more comfort and a better quality of life.5 6 22 25 </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Occlusal splint is a device that is widely used in the treatment of TMD and pain control. </plain></SENT>
<SENT sid="23" pm="."><plain>The use of an occlusal splint can lead to improvement after 1 month and even decreased pain symptoms after 1 week of use.27 Therapy with occlusal splints is the most widely used technique in dentistry for the treatment and control of pain in TMDs because it is considered to be a conservative and non-invasive treatment option. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Although clinical studies, demonstrating the benefits of both photobiomodulation treatment and occlusal splints for pain control, have been published, the cost of TMD in young patients or the cost utility of these two treatments has not been established. </plain></SENT>
<SENT sid="25" pm="."><plain>Cost-utility analysis is a method of comparing the benefits and costs of technology used in healthcare; the benefits are measured in terms of life utility.28 </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s2"><title><text><SENT sid="26" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="27" pm="."><plain>Overview </plain></SENT>
</text></title><p><text><SENT sid="28" pm="."><plain>This study aims to evaluate the cost-effectiveness of photobiomodulation therapy and occlusal splint for the treatment of pain in patients with TMD aged 15–25 years. </plain></SENT>
<SENT sid="29" pm="."><plain>This is a controlled clinical study for greater transparency and quality of this research, and table 1 provides the enrolment, intervention and assessment schedule following the Standard Protocol Items: Recommendations for Interventional Trials. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="30" pm="."><plain>Schedule of enrolment, interventions and assessments of temporomandibular disorder (TMD) treatment </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="3" align="left" colspan="1"/><td valign="top" rowspan="3" align="left" colspan="1"><text><SENT sid="31" pm="."><plain>Enrolment </plain></SENT>
</text></td><td colspan="6" align="left" rowspan="1"><text><SENT sid="32" pm="."><plain>Study period </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="left" colspan="1"><text><SENT sid="33" pm="."><plain>Allocation </plain></SENT>
</text></td><td colspan="4" align="left" rowspan="1"><text><SENT sid="34" pm="."><plain>Postallocation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35" pm="."><plain>Closeout </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="36" pm="."><plain>0 Baseline </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="37" pm="."><plain>01 month </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="38" pm="."><plain>03 months </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="39" pm="."><plain>06 months </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="40" pm="."><plain>12 months </plain></SENT>
</text></td></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1"><text><SENT sid="41" pm="."><plain>Enrolment: </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="42" pm="."><plain> Eligibility screen </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="43" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain> Informed consent </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="45" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain> Allocation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>X </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1"><text><SENT sid="48" pm="."><plain>Interventions: </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain> Photobiomodulation therapy </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>x </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain> Occlusal splint </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>x </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain> Placebo </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>x </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" rowspan="1"><text><SENT sid="67" pm="."><plain>Assessments: </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain> Pain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>x </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain> Quality of life </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>x </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>x </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain> Cost </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>x </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p><text><SENT sid="82" pm="."><plain>0=baseline, t1=01 month after the treatment, t2=03 months after the treatment, t3=06 months after the treatment, t4=12 months after the treatment. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="83" pm="."><plain>The study activities will be conducted at the Clinic of the School of Dentistry of Universidade Nove de Julho (UNINOVE). </plain></SENT>
<SENT sid="84" pm="."><plain>The project will follow the regulatory standards for ethics research with humans and will be submitted to the institutional review board of the university. </plain></SENT>
<SENT sid="85" pm="."><plain>Data collection will begin on receipt of a favourable opinion and after signed informed consent by the participants and/or their guardians. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="86" pm="."><plain>Participants </plain></SENT>
</text></title><p><text><SENT sid="87" pm="."><plain>Patients between 15 years and 25 years of age selected at the Clinic of the School of Dentistry of UNINOVE will participate in the study. </plain></SENT>
<SENT sid="88" pm="."><plain>One hundred and thirty-five patients will be selected, following the sample calculation based on studies with photobiomodulation treatment and occlusal splints, using the DINAM V.1.0 program. </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>The sample size calculation was based on literature29 and considering an average of the Visual Analogue Scale (VAS) in improving pain, pretreatment and post-treatment. </plain></SENT>
<SENT sid="90" pm="."><plain>The level of significance (alpha) being 5% with 80% power of the test, 42 patients were calculated per group. </plain></SENT>
<SENT sid="91" pm="."><plain>The sample size for this study is 135 patients (45 per group). </plain></SENT>
<SENT sid="92" pm="."><plain>Only those patients in the sample with a diagnosis of TMD will be included in groups Ia and Ib. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="93" pm="."><plain>Patient and public involvement statement </plain></SENT>
</text></title><p><text><SENT sid="94" pm="."><plain>The patients in the three groups will receive standard information about the steps of research but they will not be involved in the recruitment and conduct of the study. </plain></SENT>
<SENT sid="95" pm="."><plain>Data collection will begin on receipt of a favourable opinion and after signing of the informed consent form by the participants and/or their guardians. </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="96" pm="."><plain>Screening procedures </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>For a diagnosis of TMD (temporomandibukar disorders), the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) Questionnaire30 will be applied before any intervention. </plain></SENT>
<SENT sid="98" pm="."><plain>In addition to the questionnaire, a specific clinical examination will be conducted, always by the same previously trained evaluator, in which the patient will be positioned sitting in a chair, with their feet flat on the floor and the Camper plane parallel to the ground. </plain></SENT>
<SENT sid="99" pm="."><plain>The exam will consist of palpation of the temporalis, masseter, digastric and medial pterygoid muscles, palpation of the TMJs, and analysis of mandibular movement, using a digital pachymeter (Digimess) to measure the vertical and horizontal movements and a stethoscope to check for noises, as well as an investigation of frequent headaches, facial pain, tiredness and difficulty while chewing, bruxism, psychological aspects of adolescence and parafunctional habits. </plain></SENT>
<SENT sid="100" pm="."><plain>The RDC/TMD Questionnaire will indicate the diagnosis of myofascial TMD and the clinical examination form will analyse the mandibular movements. </plain></SENT>
<SENT sid="101" pm="."><plain>The diagnosis of pain will be evaluated by VAS and quality of life will be determined by applying the adapted EuroQol-5D (an instrument for measuring quality of life). </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="102" pm="."><plain>Preclinical trial </plain></SENT>
</text></title><sec id="s2e1"><title><text><SENT sid="103" pm="."><plain>Inclusion criteria </plain></SENT>
</text></title><p><text><SENT sid="104" pm="."><plain>Young people between 15 years and 25 years of age with a diagnosis of TMD in groups Ia and Ib (chronic myofascial pain in accordance with RDC/TMD) will be included in the study. </plain></SENT>
</text></p></sec><sec id="s2e2"><title><text><SENT sid="105" pm="."><plain>Exclusion criteria </plain></SENT>
</text></title><p><text><SENT sid="106" pm="."><plain>Group II (disk displacement of TMJ) and group III (arthralgia, arthritis, arthrosis) individuals with dental-facial anomalies who have undergone orthodontic or orthopaedic treatment of the jaws or psychological or physical therapy will be excluded. </plain></SENT>
<SENT sid="107" pm="."><plain>Individuals who were taking muscle relaxants or anti-inflammatory medications will also be excluded. </plain></SENT>
<SENT sid="108" pm="."><plain>These patients will be advised and referred for treatment, but will not participate in this study. </plain></SENT>
</text></p></sec></sec><sec id="s2f"><title><text><SENT sid="109" pm="."><plain>Randomissation </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>Participants will be divided into three groups, as shown in table 2. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="111" pm="."><plain>Distribution of participants into research groups </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Control </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>Participants </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>Therapeutic intervention </plain></SENT>
</text></td></tr></thead><tbody><tr><td valign="bottom" align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain> 1 </plain></SENT>
</text></td><td valign="bottom" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>45 </plain></SENT>
</text></td><td valign="bottom" align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>Photobiomodulation </plain></SENT>
</text></td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain> 2 </plain></SENT>
</text></td><td valign="bottom" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>45 </plain></SENT>
</text></td><td valign="bottom" align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>Occlusal splint </plain></SENT>
</text></td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain> 3 </plain></SENT>
</text></td><td valign="bottom" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>45 </plain></SENT>
</text></td><td valign="bottom" align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>Placebo </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="124" pm="."><plain>For random distribution of volunteers with TMD, will be use the randomised computer-generated list. </plain></SENT>
<SENT sid="125" pm="."><plain>Before the first evaluation, each patient will receive one number to determine the group to which they are allocated. </plain></SENT>
</text></p></sec><sec id="s2g"><title><text><SENT sid="126" pm="."><plain>Procedures </plain></SENT>
</text></title><p><text><SENT sid="127" pm="."><plain>The treatment protocols of photobiomodulation and occlusal splint presented in this study are based on clinical trials.8 16 29 31 </plain></SENT>
</text></p><p><text><SENT sid="128" pm="."><plain>The participants in the three groups will receive standard information about TDM, the complex cause of the pain and the possible contributing factors. </plain></SENT>
<SENT sid="129" pm="."><plain>The patients will be counselled to avoid the possibly stress-induced habits such as grinding, clenching, nail-biting or biting on objects like pencils, excessive gum chewing, biting and/or sucking on the lip or cheek, and pressing and/or sucking on the tongue.32 </plain></SENT>
</text></p><p><text><SENT sid="130" pm="."><plain>The baseline of this study will be 2 weeks after the patients have received standard information. </plain></SENT>
<SENT sid="131" pm="."><plain>Each treatment (G1, G2, G3) will start after 2 weeks; a patient not responding to the treatment (non-responder) will be excluded from the research sample, and offered alternative integral treatment suitable to their needs (involving psychologists, physiotherapists and so on). </plain></SENT>
<SENT sid="132" pm="."><plain>As these data are very important, the number of patients withdrawn from the study will be computed and included in the intention-to-treat (ITT) analysis. </plain></SENT>
<SENT sid="133" pm="."><plain>At the end of the research, all patients will be treated integrally to determine the major cause of this disorder. </plain></SENT>
</text></p></sec><sec id="s2h"><title><text><SENT sid="134" pm="."><plain>Treatment with photobiomodulation </plain></SENT>
</text></title><p><text><SENT sid="135" pm="."><plain>A gallium-aluminium-arsenide laser (Twinflex Evolution model, MM Optics) will be used for the photobiomodulation therapy. </plain></SENT>
<SENT sid="136" pm="."><plain>The laser therapy sessions will be performed in a reserved room next to the dental clinic offices, free from sound interference. </plain></SENT>
<SENT sid="137" pm="."><plain>At the time of the application, only the volunteer to be treated and the professional responsible for the treatment will be present, both wearing special glasses for eye protection. </plain></SENT>
<SENT sid="138" pm="."><plain>The tip of the laser will be coated with disposable transparent plastic (polyvinyl chloride (PVC)) (to avoid cross-contamination and for reasons of hygiene) and the facial site to be irradiated will be cleansed with 70% alcohol. </plain></SENT>
<SENT sid="139" pm="."><plain>During the applications the patient will remain seated, with the Frankfurt plane parallel to the ground. </plain></SENT>
</text></p><p><text><SENT sid="140" pm="."><plain>Twelve laser applications will be applied, with two sessions per week. </plain></SENT>
<SENT sid="141" pm="."><plain>A wavelength of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 s per point, resulting in a total energy of 1J per point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol.8 16 31 The laser will be applied to three points of the masseter muscle (upper, middle and lower bundles) and one point in the anterior temporalis on each side of the face.16 31 </plain></SENT>
</text></p><p><text><SENT sid="142" pm="."><plain>The patients will be called for follow-up visits at 1 month, 3 months, 6 months and 12 months after the last day of photobiomodulation therapy. </plain></SENT>
</text></p></sec><sec id="s2i"><title><text><SENT sid="143" pm="."><plain>Placebo group </plain></SENT>
</text></title><p><text><SENT sid="144" pm="."><plain>For the placebo group, all the measures described for group 1 (photobiomodulation) will be adopted, however the laser equipment will remain switched off, and a sound same as that of the equipment will be simulated with a guide light on. </plain></SENT>
<SENT sid="145" pm="."><plain>The placebo group will also have the same follow-up visits as that of group 1. </plain></SENT>
</text></p></sec><sec id="s2j"><title><text><SENT sid="146" pm="."><plain>Treatment with occlusal splints </plain></SENT>
</text></title><p><text><SENT sid="147" pm="."><plain>Stabilisation splint made with hard acrylic fabricated for the maxillary arch is the type of occlusal splint used in this study. </plain></SENT>
<SENT sid="148" pm="."><plain>The splints will be made following the principles established by literature.1 Alginate will be used to obtain the moulds of the participants' models. </plain></SENT>
<SENT sid="149" pm="."><plain>A 2 mm acetate splint will be made, to be later replaced with acrylic resin,33 and these splints will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.34 The group undergoing treatment with occlusal splints will be instructed to use the device during sleep, 8 hours every night. </plain></SENT>
<SENT sid="150" pm="."><plain>The splints will be checked after 2 weeks of use and adjusted, if needed. </plain></SENT>
<SENT sid="151" pm="."><plain>The patients will be asked to use the occlusal splints according to the instructions given to them and to return 3 months after the treatment. </plain></SENT>
<SENT sid="152" pm="."><plain>If by this visit the patient has not responded to treatment (non-responder), the researchers will offer an alternate treatment method, but these patients will be excluded from the research sample. </plain></SENT>
<SENT sid="153" pm="."><plain>The patients that have responded to the treatment will continue to use the occlusal splint and return for the 6-month follow-up visit.29 </plain></SENT>
</text></p></sec><sec id="s2k"><title><text><SENT sid="154" pm="."><plain>Evaluation of pain </plain></SENT>
</text></title><p><text><SENT sid="155" pm="."><plain>Muscle pain will be analysed by clinical criteria of the RDC/TMD Questionnaire. </plain></SENT>
<SENT sid="156" pm="."><plain>Clinical examination will be conducted periodically, and the parameters for analysis will be at intervals of 1 month, 3 months, 6 months and 12 months. </plain></SENT>
<SENT sid="157" pm="."><plain>We will use VAS to assess pain level. </plain></SENT>
</text></p></sec><sec id="s2l"><title><text><SENT sid="158" pm="."><plain>Evaluation of the impact of treatment on quality of life </plain></SENT>
</text></title><p><text><SENT sid="159" pm="."><plain>EQ-5D will be used to assess the impact of treatment on the quality of life of the participants. EQ-5D is a generic instrument for assessing the quality of life related to health. It has been developed in Europe, and translated and validated for several languages, including Portuguese.35 Because it was developed for the purpose of determining a single cardinal indicator of the state of health, it can be used for both clinical evaluation and economic evaluation. </plain></SENT>
</text></p><p><text><SENT sid="160" pm="."><plain>For this type of study, it is important that the instrument is short and simple, and represents dimensions relating to quality of life and health status.36 Currently, the original version is called EQ-5D-3L, and another version, EQ- 5D-5L, has been launched. </plain></SENT>
<SENT sid="161" pm="."><plain>EQ-5D-3L is composed of two stages, a questionnaire and a VAS. </plain></SENT>
<SENT sid="162" pm="."><plain>The questionnaire contains five questions that evaluate mobility, personal care, usual activities, pain or discomfort, and anxiety/depression. </plain></SENT>
<SENT sid="163" pm="."><plain>For each question, patients are asked to select the option that best reflects their conditions, selecting from three alternatives. </plain></SENT>
<SENT sid="164" pm="."><plain>The first alternative indicates the absence of problems, the second indicates some problems, and the third, severe problems. </plain></SENT>
<SENT sid="165" pm="."><plain>The instrument will be applied at intervals of 1 month, 3 months, 6 months and 12 months, when each group is called back for follow-up visits. </plain></SENT>
<SENT sid="166" pm="."><plain>The responses will be compared intragroup (same subject at the different follow-up intervals) and between groups. </plain></SENT>
</text></p></sec><sec id="s2m"><title><text><SENT sid="167" pm="."><plain>Cost analysis </plain></SENT>
</text></title><p><text><SENT sid="168" pm="."><plain>This phase of the study will consist of the quantification of resources, that is, determining the frequency of use of resources and materials during the treatment. </plain></SENT>
<SENT sid="169" pm="."><plain>It is a preliminary cost-effectiveness study, so we opted to analyse only direct costs. </plain></SENT>
<SENT sid="170" pm="."><plain>The units used to quantify the direct costs consumed are physical units such as consultation time, number of sessions, equipment used and materials consumed. </plain></SENT>
<SENT sid="171" pm="."><plain>These data will be collected using a specific form. </plain></SENT>
<SENT sid="172" pm="."><plain>In this phase, the prospective method of quantification of resources will be used which, according literature,37 is a method that collects information on resources according to a prior plan, in conjunction with the clinical study. </plain></SENT>
<SENT sid="173" pm="."><plain>The consumption is recorded as the actions occur. </plain></SENT>
<SENT sid="174" pm="."><plain>The resources will be assigned a value and the cost of each treatment determined for each participant and in each group studied, from the first visit to the start of the treatment until the last follow-up visit. </plain></SENT>
</text></p></sec><sec id="s2n"><title><text><SENT sid="175" pm="."><plain>Organisation and statistical treatment of the data </plain></SENT>
</text></title><p><text><SENT sid="176" pm="."><plain>The numerical data are described by means and SDs or medians and IQRs when the distribution is not presented as normal. </plain></SENT>
<SENT sid="177" pm="."><plain>The categorical variables are described by means of absolute frequencies and percentages. </plain></SENT>
<SENT sid="178" pm="."><plain>The measure of outcome used in this study will be the cost ratio and the effectiveness evaluated by muscle pain reported by the patient. </plain></SENT>
</text></p><p><text><SENT sid="179" pm="."><plain>Measurement of costs: monetary units (C) </plain></SENT>
</text></p><p><text><SENT sid="180" pm="."><plain>Measurement of effects (effectiveness): PAIN </plain></SENT>
</text></p><p><text><SENT sid="181" pm="."><plain>Treatment groups: G1 (photobiomodulation), G2 (occlusal splint) and G3 (placebo) </plain></SENT>
</text></p><p><text><SENT sid="182" pm="."><plain>Analyses: (CG1/PAING1) − (CG2/PAING2) </plain></SENT>
</text></p><p><text><SENT sid="183" pm="."><plain>CE (cost-effectiveness) = (CG1− CG2)/ (PAING1− PAING2) </plain></SENT>
</text></p><p><text><SENT sid="184" pm="."><plain>The data will be tabulated and processed using SPSS V.21.0 for Windows. </plain></SENT>
<SENT sid="185" pm="."><plain>Descriptive statistics will be used for presentation of the distribution of the variables. </plain></SENT>
<SENT sid="186" pm="."><plain>To evaluate the association of categorical variables, the χ2 and Fisher’s exact tests will be used; for the comparison of means, the Student’s t-test and analysis of variance will be used; and for the correlation analysis between continuous variables, Pearson’s correlation test will be applied. </plain></SENT>
<SENT sid="187" pm="."><plain>If subjects fail to report at a follow-up, we will use an ITT analysis. </plain></SENT>
<SENT sid="188" pm="."><plain>A t-test will be performed to compare the changes in measures within groups. </plain></SENT>
<SENT sid="189" pm="."><plain>A significance level of 95% (p&lt;0.05) will be considered. </plain></SENT>
</text></p><p><text><SENT sid="190" pm="."><plain>The study will follow the flow chart presented in figure 1. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="191" pm="."><plain>Flow chart of the search strategy. RDC/TMD, Research Diagnostic Criteria for Temporomandibular Disorders. </plain></SENT>
</text></p></caption><graphic xlink:href="bmjopen-2017-018326f01"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s3"><title><text><SENT sid="192" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="193" pm="."><plain>TMD is the most common orofacial pain and myogenic TMD is frequently the subtype. </plain></SENT>
<SENT sid="194" pm="."><plain>As TMD can be self-limiting, and the patients present with pain, loss of function and trismus, TMD affects the quality of life.38–40 Due to this, is very important to know which treatment (occlusal splint or photobiomodulation therapy) is more cost-effective for TDM pain. </plain></SENT>
</text></p><p><text><SENT sid="195" pm="."><plain>Therapy with an occlusal splint is commonly used as the basic TMD treatment in dental practice, because it is simple to manufacture, low cost and reversible, and gives more efficient results for the treatment of the most painful symptoms of TDM.32 41 </plain></SENT>
</text></p><p><text><SENT sid="196" pm="."><plain>Photobiomodulation therapy has been used to control pain in TMD and clinical studies have reported favourable results.4–7 16–24 26 However, the relationship between the cost of treatment and its effectiveness has not been established in the literature. </plain></SENT>
<SENT sid="197" pm="."><plain>Clinical and economic data evaluated together can serve as a support for decision-making in choosing a treatment or a new protocol to provide optimum conditions for affected patients. </plain></SENT>
</text></p><p><text><SENT sid="198" pm="."><plain>TMD has a multifactorial aetiology and complex dysfunction, so, the goal of this study is to evaluate the control of chronic pain of the myofascial muscles in each of the groups analysed, and not to treat TMD. </plain></SENT>
</text></p><p><text><SENT sid="199" pm="."><plain>Cost-effectiveness analysis has been used when costs are a crucial factor when choosing a certain product or technology. </plain></SENT>
<SENT sid="200" pm="."><plain>It has been considered the most suitable method of comparing two or more alternatives of a new technology in health. </plain></SENT>
<SENT sid="201" pm="."><plain>Thus, in health, economic analysis represents the evaluation of alternative choices for allocation of resources. </plain></SENT>
<SENT sid="202" pm="."><plain>It has great importance, since it evaluates and compares alternatives and facilitates the use and proper allocation of resources to spheres that may have greater benefits regarding reduction of morbidity costs or greater clinical effect.42 </plain></SENT>
</text></p><p><text><SENT sid="203" pm="."><plain>The development of a clinical and economic trial for control of muscle pain in patients with TMD provides relevant information for clinical decision-making and choosing new care protocols for inclusion. </plain></SENT>
<SENT sid="204" pm="."><plain>Through this study, we hope to obtain: data related to the direct costs of treatments with photobiomodulation therapy and occlusal splints in the treatment of muscle pain in patients with TMD; determine the ratio between the cost and effectiveness of treatments, considering pain as the end point for measuring effectiveness; and define the impact of the treatments evaluated on the quality of life of patients with TMD. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="205" pm="."><plain>Supplementary Material </plain></SENT>
</text></title><supplementary-material id="d35e221" content-type="local-data"><caption><title><text><SENT sid="206" pm="."><plain>Reviewer comments </plain></SENT>
</text></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-018326.reviewer_comments.pdf"/></supplementary-material><supplementary-material id="d35e222" content-type="local-data"><caption><title><text><SENT sid="207" pm="."><plain>Author's manuscript </plain></SENT>
</text></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-018326.draft_revisions.pdf"/></supplementary-material></sec></SecTag></body><back><fn-group><fn fn-type="other"><p><text><SENT sid="208" pm="."><plain>Contributors: Substantial contributions to the conception: APTS and LJM. </plain></SENT>
<SENT sid="209" pm="."><plain>Design of the work: CLHdG, APTS and LJM. </plain></SENT>
<SENT sid="210" pm="."><plain>Drafting the work: APTS and LJM. </plain></SENT>
<SENT sid="211" pm="."><plain>Revising the work: APTS, CLHdG, KPSF, SKB, RAMF, ACRTH, SFM and LJM. </plain></SENT>
<SENT sid="212" pm="."><plain>Final approval of the work: SKB, KPSF, APTS and LJM. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn fn-type="other"><p><text4fund><text><SENT sid="213" pm="."><plain>Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. </plain></SENT>
</text></text4fund></p></fn></SecTag><fn fn-type="COI-statement"><p><text><SENT sid="214" pm="."><plain>Competing interests: None declared. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="215" pm="."><plain>Patient consent: Obtained. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="216" pm="."><plain>Ethics approval: This study was approved the Nove de Julho University Ethics Committee, protocol number: 2.014.339. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="217" pm="."><plain>Provenance and peer review: Not commissioned; externally peer reviewed. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="R1"><text><SENT sid="218" pm="."><plain>1. OkesonJP Tratamento das desordens temporomandibulares e oclusão. Rio de Janeiro: Elsevier, 2008. </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="219" pm="."><plain>2. CarraraSV, ContiPCR, BarbosaJS Statement of the 1st consensus on temporomandibular disorders and orofacial pain. Dental Press J Orthod 2010;15:114–20. </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="220" pm="."><plain>3. MelisM, Di GiosiaM, ZawawiKH Low level laser therapy for the treatment of temporomandibular disorders: a systematic review of the literature. Cranio 2012;30:304–12. 10.1179/crn.2012.045 23156972 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="221" pm="."><plain>4. MaiaML, BonjardimLR, QuintansJS, et al Effect of low-level laser therapy on pain levels in patients with temporomandibular disorders: a systematic review. J Appl Oral Sci 2012;20:594–602. 10.1590/S1678-77572012000600002 23329239 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="222" pm="."><plain>5. de Moraes MaiaML, RibeiroMA, MaiaLG, et al Evaluation of low-level laser therapy effectiveness on the pain and masticatory performance of patients with myofascial pain. Lasers Med Sci 2014;29:29–35. 10.1007/s10103-012-1228-7 23143142 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="223" pm="."><plain>6. DostalováT, HlinakovaP, KasparovaM, et al Effectiveness of physiotherapy and GaAlAs laser in the management of temporomandibular joint disorders. Photomed Laser Surg 2012;30:275–80. 10.1089/pho.2011.3171 22551049 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="224" pm="."><plain>7. CarrascoTG, MazzettoMO, MazzettoRG, et al Low intensity laser therapy in temporomandibular disorder: a phase II double-blind study. Cranio 2008;26:274–81. 10.1179/crn.2008.037 19004308 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="225" pm="."><plain>8. CarvalhoCM, de LacerdaJA, dos Santos NetoFP, et al Wavelength effect in temporomandibular joint pain: a clinical experience. Lasers Med Sci 2010;25:229–32. 10.1007/s10103-009-0695-y 19565312 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="226" pm="."><plain>9. MariniI, GattoMR, BonettiGA Effects of superpulsed low-level laser therapy on temporomandibular joint pain. Clin J Pain 2010;26:611–6. 10.1097/AJP.0b013e3181e0190d 20664343 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="227" pm="."><plain>10. ToriiK, ChiwataI Occlusal adjustment using the bite plate-induced occlusal position as a reference position for temporomandibular disorders: a pilot study. Head Face Med 2010;6:5–12. 10.1186/1746-160X-6-5 20346167 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="228" pm="."><plain>11. Biasotto-GonzalezDA Abordagem interdisciplinar das disfunções temporomandibulares. Barueri: Manole, 2005. </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="229" pm="."><plain>12. MottaLJ, GuedesCC, De SantisTO, et al Association between parafunctional habits and signs and symptoms of temporomandibular dysfunction among adolescents. Oral Health Prev Dent 2013;11:3–7. 10.3290/j.ohpd.a29369 23507675 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="230" pm="."><plain>13. MottaLJ, MartinsMD, FernandesKP, et al Craniocervical posture and bruxism in children. Physiother Res Int 2011;16:57–61. 10.1002/pri.478 21110415 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="231" pm="."><plain>14. Oliveira de LimaC, Soares MirandaJ, Liparini CaetanoP, et al Evaluation of the life quality in patients with Temporomandibular Disorders. Braz Dent Sci 2015;18:77–83. 10.14295/bds.2015.v18i3.1144  </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="232" pm="."><plain>15. ListT, AxelssonS Management of TMD: evidence from systematic reviews and meta-analyses. J Oral Rehabil 2010;37:430–51. 10.1111/j.1365-2842.2010.02089.x 20438615 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="233" pm="."><plain>16. VenezianGC, da SilvaMA, MazzettoRG, et al Low level laser effects on pain to palpation and electromyographic activity in TMD patients: a double-blind, randomized, placebo-controlled study. Cranio 2010;28:84–91. 10.1179/crn.2010.012 20491229 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="234" pm="."><plain>17. FikáckováH, DostálováT, NavrátilL, et al Effectiveness of low-level laser therapy in temporomandibular joint disorders: a placebo-controlled study. Photomed Laser Surg 2007;25:297–303. 10.1089/pho.2007.2053 17803388 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="235" pm="."><plain>18. EmshoffR, BöschR, PümpelE, et al Low-level laser therapy for treatment of temporomandibular joint pain: a double-blind and placebo-controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:452–6. 10.1016/j.tripleo.2007.09.012 18329580 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="236" pm="."><plain>19. ShiraniAM, GutknechtN, TaghizadehM, et al Low-level laser therapy and myofacial pain dysfunction syndrome: a randomized controlled clinical trial. Lasers Med Sci 2009;24:715–20. 10.1007/s10103-008-0624-5 19002646 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="237" pm="."><plain>20. MazzettoMO, HottaTH, PizzoRCdeA Measurements of jaw movements and TMJ pain intensity in patients treated with GaAlAs laser. Braz Dent J 2010;21:356–60. 10.1590/S0103-64402010000400012 20976388 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="238" pm="."><plain>21. AhrariF, MadaniAS, GhafouriZS, et al The efficacy of low-level laser therapy for the treatment of myogenous temporomandibular joint disorder. Lasers Med Sci 2014;29:551–7. 10.1007/s10103-012-1253-6 23318917 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="239" pm="."><plain>22. MelchiorMO, VenezianGC, MachadoBC, et al Does low intensity laser therapy reduce pain and change orofacial myofunctional conditions? Cranio 2013;31:133–9. 10.1179/crn.2013.021 23795403 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="240" pm="."><plain>23. Salmos-BritoJA, de MenezesRF, TeixeiraCE, et al Evaluation of low-level laser therapy in patients with acute and chronic temporomandibular disorders. Lasers Med Sci 2013;28:57–64. 10.1007/s10103-012-1065-8 22367394 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="241" pm="."><plain>24. MelchiorMO, MachadoBC, MagriLV, et al Effect of speech-language therapy after low-level laser therapy in patients with TMD: a descriptive study. Codas 2016;28:818–22. 10.1590/2317-1782/20162015099 28001273 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="242" pm="."><plain>25. PanhocaVH, LizarelliRF, NunezSC, et al Comparative clinical study of light analgesic effect on temporomandibular disorder (TMD) using red and infrared led therapy. Lasers Med Sci 2015;30:815–22. 10.1007/s10103-013-1444-9 24197518 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="243" pm="."><plain>26. CavalcantiMF, SilvaUH, Leal-JuniorEC, et al Comparative study of the physiotherapeutic and drug protocol and low-level laser irradiation in the treatment of pain associated with temporomandibular dysfunction. Photomed Laser Surg 2016;34:652–6. 10.1089/pho.2016.4195 27898256 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="244" pm="."><plain>27. SousaFA, HortenseP, SilvaM Mensuração da dor em disfunção temporomandibular. Ver Soc Bras Estudo da dor 2003;4:95–9. </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="245" pm="."><plain>28. SanchoLG, DainS Avaliação em Saúde e avaliação econômica em Saúde: introdução ao debate sobre seus pontos de interseção. Ciência &amp; Saúde Coletiva 2012;17:765–74. 10.1590/S1413-81232012000300024 22450419 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="246" pm="."><plain>29. WahlundK, NilssonIM, LarssonB Treating temporomandibular disorders in adolescents: a randomized, controlled, sequential comparison of relaxation training and occlusal appliance therapy. J Oral Facial Pain Headache 2015;29:41–50. 10.11607/ofph.1285 25635959 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="247" pm="."><plain>30. Pereira JúniorFJ, FavillaEE, DworkinS, et al Critérios de diagnóstico para pesquisa das disfunções temporomandibulares (RDC/TMD). J. </plain></SENT>
<SENT sid="248" pm="."><plain>Bras Clin Odontol Integr 2004;47:384–95. </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="249" pm="."><plain>31. de GodoyCH, SilvaPF, de AraujoDS, et al Evaluation of effect of low-level laser therapy on adolescents with temporomandibular disorder: study protocol for a randomized controlled trial. Trials 2013;14:229 10.1186/1745-6215-14-229 23876095 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="250" pm="."><plain>32. van GrootelRJ, BuchnerR, WismeijerD, et al Towards an optimal therapy strategy for myogenous TMD, physiotherapy compared with occlusal splint therapy in an RCT with therapy-and-patient-specific treatment durations. BMC Musculoskelet Disord 2017;18:76 10.1186/s12891-017-1404-9 28183288 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="251" pm="."><plain>33. OkesonJP Dor orofacial: guia de avaliação, diagnóstico e tratamento, quintessence. 1998:1–18. </plain></SENT>
</text></ref><ref id="R34"><text><SENT sid="252" pm="."><plain>34. StriniP, CunhaGS, JúniorRB, et al Alterações biomecânicas em pacientes portadores de Disfunção Temporomandibular antes e após o uso de dispositivos oclusais. 2009;17:42–7. </plain></SENT>
</text></ref><ref id="R35"><text><SENT sid="253" pm="."><plain>35. KristensenF, SigmundH Health technology assessment handbook, Danish centre for health technology assessment. Copenhagen: National Board of Health, 2008. </plain></SENT>
</text></ref><ref id="R36"><text><SENT sid="254" pm="."><plain>36. FerreiraPL, FereiraL, NoronhaL, et al Contributos para a validação da versão Portuguesa do EQ-5D. Acta Médica Portuguesa 2013;26:664–75.24388252 </plain></SENT>
</text></ref><ref id="R37"><text><SENT sid="255" pm="."><plain>37. FerreiraPL, SantanaP Percepção de estado de saúde e de qualidade de vida da população activa: contributo para a definição de normas portuguesas. Revista portuguesa de saúde pública 2003;2:15–30. </plain></SENT>
</text></ref><ref id="R38"><text><SENT sid="256" pm="."><plain>38. MaixnerW, DiatchenkoL, DubnerR, et al Orofacial pain prospective evaluation and risk assessment study--the OPPERA study. J Pain 2011;12(Suppl):T4–T11.e2. 10.1016/j.jpain.2011.08.002 22074751 </plain></SENT>
</text></ref><ref id="R39"><text><SENT sid="257" pm="."><plain>39. LeRescheL Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev Oral Biol Med 1997;8:291–305. 10.1177/10454411970080030401 9260045 </plain></SENT>
</text></ref><ref id="R40"><text><SENT sid="258" pm="."><plain>40. ManfrediniD, LobbezooF Relationship between bruxism and temporomandibular disorders: a systematic review of literature from 1998 to 2008. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:e26–e50. 10.1016/j.tripleo.2010.02.013  </plain></SENT>
</text></ref><ref id="R41"><text><SENT sid="259" pm="."><plain>41. PorteroPP, KernR, KusmaSZ Grau-Grullón P."Placas oclusais no tratamento da disfunção temporomandibular (DTM).". Rev Gest &amp; Saúd 2009:36–40. </plain></SENT>
</text></ref><ref id="R42"><text><SENT sid="260" pm="."><plain>42. MorazG, GarcezAdaS, AssisEMde, et al Estudos de custo-efetividade em saúde no Brasil: uma revisão sistemática. Ciência &amp; Saúde Coletiva 2015;20:3211–29. 10.1590/1413-812320152010.00962015 26465862 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
